Eylul joined NEA in 2015 as an associate and focuses on healthcare investments. She is a board observer for DOTS Technology Corp and Eargo. She is also actively involved with NEA’s investments in Cleave Biosciences, Intrinsic Therapeutics, Moximed, Neotract, Setpoint and Willow. Prior to joining NEA, Eylul was a member of Morgan Stanley’s Healthcare Investment Banking and Equity Capital Markets teams where she was engaged in M&A and equity transactions for more than 30 unique companies in the healthcare space, including NEA portfolio companies such as Nevro and Tesaro.

Eylul graduated from Columbia University, with a B.A. in Economics and Mathematics.


  • Robert College
    2003–2008 Robert College High School
  • Columbia
    2008–2012 Columbia University
  • Morgan Stanley
    2012–2015 Morgan Stanley
  • NEA
    2015–Current NEA